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CRISPR-Cas9 deletion (CRISPR-del) is the leading approach for eliminating DNA from mammalian cells and underpins a
variety of genome-editing applications. Target DNA, defined by a pair of double-strand breaks (DSBs), is removed during
nonhomologous end-joining (NHEJ). However, the low efficiency of CRISPR-del results in laborious experiments and false-
negative results. By using an endogenous reporter system, we show that repression of the DNA-dependent protein kinase
catalytic subunit (DNA-PKcs)—an early step in NHEJ—yields substantial increases in DNA deletion. This is observed across
diverse cell lines, gene delivery methods, commercial inhibitors, and guide RNAs, including those that otherwise display
negligible activity. We further show that DNA-PKcs inhibition can be used to boost the sensitivity of pooled functional
screens and detect true-positive hits that would otherwise be overlooked. Thus, delaying the kinetics of NHEJ relative to
DSB formation is a simple and effective means of enhancing CRISPR-deletion.
[Supplemental material is available for this article.]
CRISPR-Cas9 technology enables a variety of loss-of-function per-
turbations to study the functions of genomic elements in their
natural context and engineer natural and unnatural mutations
(Cong et al. 2013; Mali et al. 2013; Doench 2018). One such ap-
plication, CRISPR deletion (CRISPR-del), is the primary means of
permanently removing targeted genomic regions. CRISPR-del
uses a pair of CRISPR-Cas9 complexes to introduce double-strand
breaks (DSBs) at two sites flanking the target region. Paired DSBs
are repaired by the endogenous nonhomologous end-joining
(NHEJ) pathway, which frequently ejects the intervening frag-
ment, resulting in a genomic deletion (Yang et al. 2013;
Maddalo et al. 2014; Ho et al. 2015; Vidigal and Ventura 2015).
Less frequently, the target region may be inverted without dele-
tion (Canver et al. 2014; Antoniani et al. 2018; Watry et al.
2020). Cas9 complexes are recruited to the two edges of the target
region via a user-defined pair of single guide RNAs (sgRNAs, or
“pgRNAs” for the pair) (Pulido-Quetglas et al. 2017), delivered
by transfection or viral transduction (Aparicio-Prat et al. 2015;
Vidigal and Ventura 2015).
CRISPR-del has been used to successfully remove genomic re-
gions from 101 to 106 bp (Canver et al. 2014). This range has en-
abled researchers to test the function of a variety of genomic
elements, including gene regulatory sequences (Canver et al.
2015; Mochizuki et al. 2018; Gasperini et al. 2019), noncoding
RNAs (Han et al. 2014; Ho et al. 2015; Holdt et al. 2016; Koirala
et al. 2017; Xing et al. 2017), and structural elements (Huang
et al. 2018). Engineered deletions have also been used tomodel hu-
man mutations (Lupiañez et al. 2015; Nelson et al. 2016).
CRISPR-del is readily scaled to high-throughput pooled
screens, delivered via lentiviral libraries of thousands of pgRNAs
(Aparicio-Prat et al. 2015; Vidigal and Ventura 2015). This has
been used to discover long noncoding RNAs (lncRNAs) regulating
cancer cell proliferation (Zhu et al. 2016; Liu et al. 2018) and to
map cis-regulatory regions of key protein-coding genes (Diao
et al. 2017; Gasperini et al. 2017). Screens are most commonly per-
formed in transformed cell lines, for reasons both scientific (iden-
tification of novel cancer genes) and practical (requirement for
large and homogeneous cell populations) (Zhu et al. 2016; Liu
et al. 2018; Esposito et al. 2019). Lentiviral delivery of pooled li-
braries introduces practical constraints, requiring both sgRNAs of
a pair to be encoded in a single vector (to ensure simultaneous
delivery), and low multiplicity of infection (MOI; for each cell to
receive a low number of perturbations) (Vidigal and Ventura
2015; Zhu et al. 2016; Gasperini et al. 2017; Doench 2018;
Esposito et al. 2019).
The principal drawback of CRISPR-del is the low efficiency
with which targeted alleles are deleted. Studies on cultured cells
typically report efficiencies in the range 0%–50% of alleles, and of-
ten <20% (Mandal et al. 2014; Thomas et al. 2020), with similar es-
timates from individual clones (Canver et al. 2014; Aparicio-Prat
et al. 2015; Ho et al. 2015; Vidigal and Ventura 2015; Pulido-
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Quetglas et al. 2017). Indeed, a recent publication reported high
variation in the efficiencies of pgRNA targeting the same region,
including many that yielded negligible deletion (Thomas et al.
2020). Transfection typically yields greater efficiency than viral
transduction, possibly owing to higher sgRNA levels (Mangeot
et al. 2019), but is incompatible with pooled screening. Low dele-
tion efficiency introduces the need to isolate homozygous knock-
out clones by laborious expansion of hundreds of single cells
(Aparicio-Prat et al. 2015). Resulting clonesmay not be representa-
tive of the general population (Stojic et al. 2018).
More important than these practical costs, is the potential im-
pact of low deletion rates on the ability to discern bona fide func-
tional effects arising from a given mutation (Thomas et al. 2020).
Nonperforming pgRNAs are a particular problem for pooled
CRISPR-del screens, where they reduce statistical power and lead
to false-negative results. To overcome this, researchers are obliged
to increase the number of deletion constructs per target and the
number of cells screens, resulting in lower throughputs and in-
creased costs (Doench et al. 2016; Sanson et al. 2018).
Consequently, any method to improve CRISPR-del efficiency
promises to streamline experiments and promote the discovery
of presently overlooked functional elements.
CRISPR-del depends on NHEJ, the principal pathway for re-
pairing Cas9-induced DSBs (Brinkman et al. 2018). In mammalian
cells, the NHEJ pathway is divided in three steps: (1) DSB recogni-
tion and end binding, in which the exposed DNA ends are recog-
nized by the Ku70/80 complex (Chang et al. 2017); (2) end
processing (resection of mismatched nucleotides and DNA resyn-
thesis), based on activation of the nuclease Artemis and Pol X fam-
ily polymerases by the serine-threonine kinase DNA-PKcs (Chang
et al. 2017); and (3) end ligation by DNA ligase complex (DNA li-
gase 4, XRCC4, and XLF) (Chang et al. 2017).
For some applications of CRISPR, notably precise genome ed-
iting using homologous recombination (HR), efficiency can be
substantially improved through pharmaceutical strategies (Yeh
et al. 2019). Here, editing events are rare, and HR is the rate-limit-
ing step (Mao et al. 2008; Miyaoka et al. 2016). Two alternative
strategies have been successful: (1) direct stimulation of homolo-
gy-directed repair (HDR) (Lin et al. 2014a; Song et al. 2016;
Riesenberg and Maricic 2018; Yeh et al. 2019); (2) suppression of
the competing NHEJ pathway at early stages through inhibition
of Ku70/80 complex (Fattah et al. 2008; Riesenberg and Maricic
2018; Yeh et al. 2019) or DNA-dependent protein kinase catalytic
subunit (DNA-PKcs) (Robert et al. 2015; Riesenberg and Maricic
2018; Riesenberg et al. 2019; Yeh et al. 2019) or, at late phases,
via DNA ligase 4 inhibition (Chu et al. 2015; Maruyama et al.
2015; Riesenberg andMaricic 2018; Yeh et al. 2019). To date, how-
ever, there are no reportedmethods for pharmacological enhance-
ment of CRISPR-del.
Upon paired DSB, NHEJ can promote several distinct out-
comes: (1) the intermediate fragment is removed, and the distal
DNA edges ligated (leading to successful deletion); (2) each of
the two DSB is repaired independently, leaving small indels at
both target sites (no deletion); (3) the intermediate fragment is
flipped, and the DSB are repaired (creating an inversion). A fourth
possibility is that DSBs are repaired via HDR using the sister’s chro-
matid as a template, which can be retargeted by the CRISPR com-
plex. Systematic studies have concluded that genomic deletion is
only the second most frequent outcome, after scenario 2 (up to
70% of the cases) (Canver et al. 2014; Antoniani et al. 2018).
This implies that the greatest impedi-
ment to CRISPR-del is the process in
which both DSBs occur at different
times, creating genomic scars that pre-
vent further deletion. Only when both
CRISPR complexes act in a synchronized
fashion can deletion occur (Fig. 1A).
From this, we hypothesize that deletion
will be favored when paired DSBs occur
on a timescale shorter than that required
for NHEJ.
A prediction of this, is that deletion
can be promoted by reducing the rate of
NHEJ, thereby increasing the likelihood
that both DSBs co-occur. Here, we test
this hypothesis, by examining the effect
on CRISPR-del efficiency of pharmaco-
logically slowing the rate of NHEJ during
DSB formation, through the inhibition
of DNA-PKcs (iDNAPKcs).
Results
A quantitative endogenous reporter
for CRISPR-del
CRISPR-del is an important loss-of-
function perturbation for both low- and
high-throughput studies, yet its rela-
tively low efficiency remains a major im-




Figure 1. Poor deletion efficiency of paired sgRNAs and CRISPR-deletion (CRISPR-del) model. (A)
Reanalysis of significant growth-promoting gene “hits” identified in the CRISPR-del negative selection
screen in Huh7 cells from Zhu et al. (2016). Each hit is targeted by several individual paired sgRNAs.
Histogram displays the percentage of paired sgRNAs that effectively perturb their target gene. The
dashed line represents the median (42.9%). (B) Scatterplot displays paired sgRNAs targeting gene hits
from A. The x-axis indicates the mean of the two sgRNAs predicted on-target efficiency (calculated
with the Rule Set II scoring algorithm from Doench et al. 2016); y-axis, log2-transformed fold-change
in paired sgRNA detection after cell passaging (growth phenotype). R indicates Pearson’s correlation;
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screen, in which growth promoting genes were each targeted by
several pgRNAs (Zhu et al. 2016). Less than half of pgRNAs target-
ing “hit” genes yielded a detectable phenotype, indicating that the
majority of screened pgRNAs do not efficiently delete their targets
(Fig. 1B). Similar results were reported by Canver et al. (2014),
where 65% of pgRNAs yielded deletion efficiency <20% (Canver
et al. 2014). Furthermore, therewas no correlation between pheno-
type and average on-target score of the two sgRNAs (Fig. 1C; Zhu
et al. 2016), suggesting that deletion efficiency does not simply
depend on the aggregate of sgRNA quality.
To identify factors capable of improving CRISPR-del efficien-
cy, we designed a gene-based reporter system: CRISPR Deletion
Endogenous Reporter (CiDER). Such a system should be quantita-
tive, sensitive, and practical and be able to closely model the
CRISPR-del process by targeting endogenous genes rather than
plasmids. We focused on genes encoding cell-surface proteins, as
they can be rapidly and sensitively detected by flow cytometry
(Bausch-Fluck et al. 2015). A number of candidates were consid-
ered with criteria of (1) nonessentiality for cell viability and prolif-
eration (Luo et al. 2008; Meyers et al. 2017; Tsherniak et al. 2017;
https://depmap.org), (2) high expression in human cell lines (Thul
et al. 2017; http://www.proteinatlas.org), (3) lack of overlap with
other genomic elements that could lead to false-positive detection,
and (4) availability of flow cytometry grade antibody. Consequent-
ly, we selected PLXND1 encoding the plexin D1 protein (Supple-
mental Fig. S1), present in three genomic copies in HeLa cells
and HEK293T and two in HCT116 cells (Cancer Cell Line Encyclo-
pedia [CCLE]) (Barretina et al. 2012; Lin et al. 2014b; https
://portals.broadinstitute.org/ccle/data; www.hek293genome.org).
We conceived an experimental setup in which successful
CRISPR-del leads to loss of PLXND1 expression but unsuccessful
events do not. In this scheme, the gene’s first exon is targeted
for deletion by a series of pgRNAs recognizing the non-protein-
coding regions upstream (promoter) and downstream (first intron)
(Fig. 2A). Successful deletions of the first exon are expected to si-
lence protein expression, but indels from individual sgRNAs do
not affect the protein sequence directly and should not lead to si-
lencing. It should also be noted that inversions will also silence
plexin D1 expression and be called as mutations by this reporter,
and therefore, results should be interpreted with care. Finally, we
also designed a control pgRNA that directly targets the open read-
ing frame (ORF), expected to yieldmaximal protein silencing inde-
pendent of deletion (designated positive control, P+).
We used flow cytometry to evaluate plexin D1 protein
levels (Fig. 2B). Positive control sgRNAs (P+) yielded ∼90% knock-
out efficiency. We observed wide variability in the deletion effi-
ciency of pgRNAs, from Pair1 (P1), displaying minimal efficacy,
to the most efficient P4, yielding ∼40% deletion. Therefore, these
pgRNAs achieve deletion efficiencies that are comparable to
previous studies (Canver et al. 2014; Pulido-Quetglas et al.
2017). Measured deletion rates were consistent across biological
replicates (Fig. 2B).
We next assessed whether flow cytometry was a good surro-
gate for genomic deletion and whether loss of plexin D1 expres-
sion required mutation of all alleles within a cell. To do so, we
separated plexin D1–negative and plexin D1–positive cell popula-
tions via fluorescence-activated cell sorting (FACS) and detected
remaining “wild-type” alleles (referring to nondeleted and
noninverted alleles) with a genomic quantitative PCR (quantita-
tive CRISPR PCR [QC-PCR]) (Pulido-Quetglas et al. 2017). We ob-
served that plexin D1–negative cells show an almost complete
loss of wild-type alleles (Fig. 2C; note the inverted scale used for
QC-PCR). In summary, the flow cytometry–based CiDER assay is
conservative: It classifies only homozygous knockout cells as “mu-
tant,” and remaining wild-type and heterozygous cells as “wild
type.” Furthermore, the greater a cell’s ploidy for PLXND1, the
more stringent this definition becomes.
Finally, the observed loss of plexin D1 was not owing to large
indels or disruption of gene regulatory elements at individual
sgRNA target sites (Kosicki et al. 2018), because control experi-
ments with single sgRNAs showed no loss of plexin D1
(Supplemental Fig. S2). In CiDER, wehave a reproducible and prac-
tical reporter of CRISPR-del at a range of efficiencies.
Inhibition of DNA-PKcs during DSB formation increases
CRISPR-del efficiency
We hypothesized that reducing the rate of NHEJ during DSB for-
mation would favor CRISPR-del, by increasing the chance that
both DSBs will co-occur (Fig. 1A). We tested DNA-PKcs, a DNA
end-binding factor at the first step of NHEJ pathway, for which a
number of small-molecule inhibitors are available (Harnor et al.
2017). We began by treating HeLa cells with the inhibitor
M3814 (IC50 = 3 nM) (Fuchss et al. 2014; Zenke et al. 2016;
Riesenberg et al. 2019) at two concentrations (300 and 900 nM).
Importantly, cells constitutively expressing Cas9 were treated for
an 18-h time window, 4 h after sgRNA plasmid delivery by trans-
fection. Thus, DNA-PKcs was inhibited immediately before
sgRNA expression. This resulted in improved deletion rates for all
four pgRNAs, including a 17-fold increase for P1, which otherwise
displays negligible deletion under normal conditions (Fig. 2D,E;
Supplemental Fig. S3A,B).
The effect of inhibition of DNA-PKcs (iDNA-PKcs) was con-
centration dependent, and concentrations <300 nM were ineffec-
tive (Supplemental Fig. S4A). Inhibition of DNA-PKcs for <18 h did
not improve CRISPR-del efficiency, whereas longer treatments
showed slightly improved deletion rates (Supplemental Fig. S4B).
Chronic iDNA-PKcs can be toxic for some cell types; therefore,
we opted for 18-h treatments in this study. We hypothesized
that observed improvements of CRISPR-del are a consequence of
repression, but not complete abolition, of DNA-PKcs and NHEJ ac-
tivity. Consistent with this, we evaluated levels of active (phos-
pho) DNA-PKcs under conditions used here (M3814 300 nM, 18-
h treatment), and observed substantial residual activity
(Supplemental Fig. S4C). Similar observationswere recently report-
ed by Zenke et al. (2020).
We next investigated whether iDNA-PKcs alters the nature of
editing events taking place at target sites. We performed Sanger se-
quencing at a number of deleted alleles and observed amild reduc-
tion in the preciseness of editing (Supplemental Fig. S5A,B).
A more important issue is the potential effect of iDNA-PKcs
on inversion rates: It is possible that CiDER miscalls increase
in inversions as the observed increases in deletions. The literature
indicates that inversions occur at nonnegligible rates, but less
frequently than deletions. Canver et al. (2014) estimated an overall
deletion rate, across 17 targets of varying size, to occur at approx-
imately one-third the rate of deletions (5.8% vs. 14.2%, respective-
ly). A more recent study found this ratio to be approximately
one-half (Watry et al. 2020). We evaluated how this might affect
our results. First, we cloned and sequenced nondeleted alleles
from vehicle and M3814-treated HeLa and observed a similar
rate of inversions (8/14 cases and 8/17 cases, respectively)
(Supplemental Fig. S7A,C). Second, we used quantitative PCR
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(Supplemental Fig. S3C), observing either no change in inversion
rates (HeLa, HEK293T) or a moderate approximately 1.5-fold in-
crease, less than the overall approximately 2.5-fold gain in loss
of function (HCT116) (Fig. 3B). In summary, this leads us to con-
clude that observed change in loss of function we observe owing
to iDNA-PKcs is mainly attributable to deletions.
Our hypothesis also predicts that
other inhibitors of DNA-PKcs yield a sim-
ilar effect. We treated cells with four oth-
er commercially available inhibitors
at a concentration of 10 µM: KU57788
(IC50 = 14 nM), NU7026 (IC50 = 230
nM), LTURM34 (IC50 = 34 nM), and
DMNB (IC50 = 15 µM) (Fig. 2F). Each
one yielded increases in CRISPR-del effi-
ciency to varying degrees, correlating
with published differences on the inhibi-
tion potency (Mohiuddin and Kang
2019). As expected based on previous lit-
erature, KU57788 gave the strongest ef-
fect (Mohiuddin and Kang 2019), and
DMNB gave the weakest effect, likely ow-
ing to its high IC50.
We were curious whether improved
deletion depends on inhibition specifi-
cally of DNA-PKcs or more generally on
NHEJ. To answer this, we used SCR7 pyr-
azine to inhibit another step inNHEJ, the
final ligation by DNA ligase 4. In contrast
to iDNA-PKcs, this treatment did not im-
prove deletion efficiency (Fig. 3A). This
might be expected, because at this late
stage, the NHEJ machinery (DNA end-
binding and processing complex) has al-
ready brought together the free DNA
ends. Thus, CRISPR-del efficiency im-
provements depend specifically on inhi-
bition of DNA-PKcs activity. Altogether,
we have shown that pharmacological in-
hibition of NHEJ at the DNA-PKcs step
yields enhanced deletion of PLXND1 re-
porter in HeLa cells.
Generality of deletion enhancement
by DNA-PKcs inhibition
We next assessed whether iDNA-PKcs is
more generally effective across cell lines,
genomic targets, and sgRNA delivery
modalities.
We began by replicating CiDER ex-
periments in two widely used cell lines,
HCT116 and HEK293T (Fig. 3B; Hart
et al. 2015; Li and Richard 2016; Liu
et al. 2017; Thomas et al. 2020). Both
have baseline CRISPR-del efficiency be-
low HeLa, possibly owing to weaker
NHEJ activity (Miyaoka et al. 2016).
Nevertheless, iDNA-PKcs enhanced dele-
tion in both cell backgrounds.
We next assessed whether these ef-
fects hold for other loci. We previously
established QC-PCR to measure rates of deletion at the MALAT1
enhancer region (see primer setup in Fig. 3C, central panel;
Pulido-Quetglas et al. 2017). For three out of four pgRNAs, we ob-
served a significant enhancement of deletion with M3814 treat-
ment of HeLa (Fig. 3C). It should be noted that the pgRNAs used







Figure 2. CiDER reporter system identifies DNA-PKcs inhibition as a means to increase CRISPR-del ef-
ficiency. (A) The CiDER endogenous reporter relies on a series of sgRNA pairs targeting exon 1 of PLXND1
gene, whose protein product is detected by flow cytometry. (B) CiDER measurements of CRISPR-del ef-
ficiency over a range of times between sgRNA delivery and cell harvesting (mean, standard deviation). (C)
Independent evaluation of CRISPR-del efficiency in sorted plexin D1–negative and D1–positive cells.
(Top) Representative fluorescent activated cell sorting (FACS) plot. Plexin D1–negative (APC-) and
Plexin D1–positive cells (APC+) are gated. (Bottom) The fraction of nondeleted alleles in each population
quantified by qPCR (mean, standard deviation). The black bar corresponds to a nontargeting control
used for normalization. Green bars correspond to sorted HeLa cells with pgRNAs targeting PLXND1
(P3). (D) CRISPR-del efficiency measured by CiDER in HeLa upon DNA-PKcs inhibition (mean, standard
deviation, one-tailed paired t-test). (E, top) Representative raw flow cytometry plots for HeLa upon
DNA-PKcs inhibition. Plexin D1–positive cells are gated, and numbers correspond to percentage of cells.
(Bottom) Representative images of individual sorted, stained HeLa cells. (F ) CiDER measurements of
CRISPR-del efficiency in HeLa upon DNA-PKcs inhibition with indicated small molecules (values: mean
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scope for large improvements in deletion efficiency. Similar but
weaker results were also observed for HCT116 (two out of four
pairs) and HEK293T cells (one out of four pairs) (Supplemental
Fig. S6A,B).We confirmed thatM3814 treatment does not substan-
tially alter the nature of editing at deleted junctions by Sanger se-
quencing (Supplemental Fig. S7A,B). We next assessed whether
nondeleted alleles carry genomic scars at the sgRNA sites.
Becausewe did notmanage to amplify the full-length PCR product
from PLXND1, we amplified nondeleted alleles from the MALAT1
enhancer region and performed Sanger sequencing of one of the
junctions. We detected high rates of sgRNA-disrupting mutations
at target sites (5/6 for untreated, 5/9 for treated samples), support-
ing the notion that mutations from uncoordinated DSBs prevent
subsequent deletion (Supplemental Fig. S7A,C).
CRISPR-del is often used to edit nontransformed cells; there-
fore, we sought to test the effectiveness of iDNA-PKcs under such
conditions. However, poor delivery of Cas9 was a substantial im-
pediment in the various human primary fibroblast cell types we
tested. In human induced pluripotent cells (hiPSCs), we managed
to deliver Cas9 protein and sgRNAs and
observed promising but not statistically
significant increase in deletion with
M3814 treatment in three biological rep-
licates (Supplemental Fig. S8; Supple-
mental Methods). Future studies will be
dedicated to optimize CRISPR-del in plu-
ripotent and other nontransformed cells.
Taken together, these findings sup-
port the general applicability of iDNA-
PKcs for boosting CRISPR-del, although
optimization will likely be required on a
cell-by-cell basis.
DNA-PKcs inhibition boosts sensitivity
of high-throughput pooled screens
One particularly powerful application
of CRISPR-del is in pooled functional
screens (Esposito et al. 2019). Here, li-
braries of pgRNAs are delivered by lenti-
virus to cultured cells, and phenotypic
consequences of deleting hundreds to
thousands of genomic elements can be
assayed in parallel.
We first askedwhether iDNA-PKcs is
practical under these conditions, by tar-
geting the PLXND1 reporter with sgRNAs
delivered by standard low-MOI lentiviral
infection. In initial experiments, M3814
was added to cell media at the same
time of lentiviral transduction, but al-
most no improvement in deletion effi-
ciency was observed (Supplemental Fig.
S9A). This is explained by the fact that
lentiviruses require NHEJ for genomic in-
tegration (Li et al. 2001; Daniel et al.
2004). Therefore, we modified our proto-
col so as to leave sufficient time for viral
integration before NHEJ inhibition (24
h was optimal) (Supplemental Fig. S9B).
This resulted in a 2.7-fold increase in
CRISPR-del efficiency (Fig. 3D).
Cell population is a widely used phenotypic readout of
pooled screens, not only for its practicality but also because it is
a proxy for fitness and can identify genes required for enhanced
growth or survival of cancer cells (Doench 2018; Esposito et al.
2019). To test whether improved CRISPR-del translates into stron-
ger phenotypes, we developed a simple assay for the effect of
CRISPR-del on cell survival. Analogous to PLXND1 (Fig. 2A), we de-
signed three pgRNAs targeting the first exon (but not ORF) of the
essential gene, RPS5 (coding for the 40S ribosomal protein S5,
P46782, UniProt): RPS5-P9, P10, P11. As expected, sgRNAs target-
ing the AAVS1 locus had no effect, whereas positive control
sgRNAs targeting the RPS5ORF (RPS5-P+) resulted in∼47%mortal-
ityafter72h (Fig. 4A). pgRNAs targeting the first exon (P9,P10,P11)
resulted in a substantialmortality (32%, 21%, and 15%, respective-
ly), whichwas significantly enhanced by addition ofM3814 (41%,
30%, and 22%, respectively). Therefore, pharmacologically im-
proved CRISPR-del yields enhanced cellular phenotypes.
We sought to test the benefit of iDNA-PKcs in a realistic fit-




Figure 3. DNA-PKcs inhibition boosts CRISPR-del independent of cell, readout, or sgRNA delivery
method. (A) CRISPR-del efficiency of CiDER in HeLa upon DNA ligase 4 inhibition (mean). (B) CiDERmea-
surement of CRISPR-del efficiency in HCT116 and HEK293T cell lines upon DNA-PKcs inhibition (mean,
standard deviation, one-tailed paired t-test). (C) CRISPR-del efficiency at MALAT1-enhancer upon DNA-
PKcs inhibition. (Left) The fraction of WT allele quantified by qPCR (mean, standard deviation, one-tailed
paired t-test). (Center) The pgRNAs, PCR primers, and a representative agarose gel from the genomic PCR
of the region. (Right) Quantification of the KO band from the gel. (D) CRISPR-del efficiency of CiDER in
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2019). To do so, we created a library of pgRNAs targeting positive-
control essential genes (348 pgRNAs, 59 target genes) and neutral-
control intergenic regions (632 pgRNAs, 65 target regions) (Fig.
4C). Similar to above, pgRNAs for positive control regions flanked
the gene TSS without targeting the ORF, so that loss of fitness
should only be observed in the case of a deletion (Fig. 4A). We
transduced Cas9-expressing HeLa (cervical carcinoma) with this li-
brary at low MOI (0.35) and then divided them into two popula-
tions, one of which was treated with M3814 (18 h, 300 nM).
Cells were passaged for periods of 1 and 3 wk, to allow loss of fit-
ness to manifest in decreases in pgRNA populations (“drop out”),
and then pgRNA populations were counted by deep massively
parallel sequencing.
We observed that M3814 treatment significantly enhanced
drop-out of pgRNAs targeting essential genes, but not neutral con-
trols, after 1 wk (Fig. 4D,F,G) and 3 wk (Supplemental Fig. S10B).
Although we observed the expected inverse relationship between
deletion size and efficiency (Canver et al. 2014), there was no pref-
erence for M3814 to increase the rate of shorter or longer deletions
(Supplemental Fig. S10C). Next we combined the results from in-
dividual pgRNAs to identify significant gene hits, and we could
correctly identify essential genes with greater sensitivity in
M3814-treated versus untreated cells after 1 wk (16/59 27.1%%
vs. 8/59 13.5%, respectively) and 3 wk (17/59 28.8% vs. 13/59
22.0%, respectively) (Fig. 4E). More generally, gene-level false-dis-
covery rates (FDRs) were consistently lower in M3814-treated cells
(Fig. 4E). On the contrary, M3814 led to no increase in false-posi-
tive predictions, as measured by neutral targets called as hits (Fig.
4E). A replicated screen athigherMOI (0.6) yielded similar findings
(Supplemental Fig. S10A,B). In conclusion, pharmacological inhi-
bition of DNA-PKcs can be used to improve the sensitivity of
pooled functional screens based on CRISPR-del.
Discussion
The intrinsic DNA damage response underpins CRISPR-Cas9 ge-
nome editing and may be manipulated to favor desired editing
outcomes. In the case of precise genome editing, efficiency has
been substantially improved through pharmacological promotion
of HDR and inhibition of the competing NHEJ pathway (Yeh et al.
2019). No such solutions have been developed for CRISPR-del, de-
spite its being one of the most common CRISPR-Cas9 modalities
with diverse scientific and technological applications (Han et al.
2014; Canver et al. 2015; Ho et al. 2015; Lupiañez et al. 2015;
Holdt et al. 2016; Nelson et al. 2016; Koirala et al. 2017; Xing
et al. 2017; Huang et al. 2018; Mochizuki et al. 2018; Gasperini
et al. 2019).
We hypothesized that successful CRISPR-del requires paired
DSBs to co-occur before NHEJ has time to act and thus may be en-
hanced by pharmacological inhibition of DNA-PKcs. This is initial-
ly counter-intuitive, as DNA-PKcs is a necessary step in the NHEJ
pathwayuponwhichCRISPR-del relies, and its inhibition is widely
used to promote the competing HDR pathway (Robert et al. 2015;
Riesenberg and Maricic 2018; Riesenberg et al. 2019; Yeh et al.
2019). However, rather than permanently blockingNHEJ, our pro-
tocol inhibits NHEJ to reduce the kinetics of DSB formation, pre-
sumably increasing the chance of two events co-occurring. This
results in a significant enhancement of DNA deletion efficiency.
DNA-PKcs inhibition represents a practical option for a varie-
ty of CRISPR-del applications, from basic research to gene therapy.
DNA-PKcs inhibitors are cheap and widely available. Deletion effi-
ciency improved regardless of the inhibitor molecule, target re-
gion, sgRNA sequence, cell background, and delivery method.
The exceptionwas for nontransformed cells, where promising pre-
liminary data were obtained in iPSCs, but extensive optimization
of Cas9 delivery and treatment conditions will be necessary before
concluding whether iDNA-PKcs is effective here. Particularly strik-
ing was the observation that a pgRNA that is ineffective under
normal conditions achieved respectable rates of deletion with
iDNA-PKcs (P1 in Fig. 2D). This suggests that the failure of many
pgRNAs to efficiently delete DNA may arise not from their inabil-
ity to promote DSBs but rather as a result of poor kinetic properties
(e.g., a mismatch in kinetics between the two individual sgRNAs).
Finally, this method (with minor modifications) is compatible
with low-MOI lentiviral delivery and led to impressive gains in sen-
sitivity of a pooled functional screen, an approach with rapidly
growing adoption (Zhu et al. 2016; Diao et al. 2017; Gasperini
et al. 2017; Liu et al. 2018).
The CiDER method presented here has wide applications in
identifying intrinsic and extrinsic factors that modulate CRISPR-
del efficiency. Its advantages include simplicity, practicality, and
faithful representation of the deletion process in cellular chroma-
tin. However, it is incapable of distinguishing deletion from inver-
sion, the latter being a nonnegligible editing outcome. In the
future, it will be important to use methods capable of distinguish-
ing deletion and inversion events, such as digital droplet PCR
(ddPCR) (Antoniani et al. 2018; Watry et al. 2020), although it
might not be practical for testing large numbers of samples and
conditions. Although the CiDER and qPCR assays used here could
not explicitly distinguish the ratios of deletion and insertion aris-
ing from pgRNA targeting, we found that most of the measured
iDNA-PKcs-dependent changes arise from increases in deletion.
Methods
Reanalysis of CRISPR-del screen data
Raw and processed data were obtained from Zhu et al. (2016).
sgRNA pairs were defined to contribute to a gene-level phenotype
(Fig. 1A) based on the “good sgRNAs” column in Supplementary
Table 5 of Zhu et al. (2016). To generate the results in Figure 1B,
massively parallel sequencing data from the negative selection
screen in Huh7 cells was reanalyzed using the MAGeCK algorithm
(Li et al. 2014; https://sourceforge.net/p/mageck/wiki/Home/) to
obtain the log2 fold-change (LFC) for each pgRNA. As the purpose
of our analysis was to examine deletion efficiency, and sgRNAs tar-
geting an ORF can inactivate a gene independent of deletion, we
excluded pgRNAs having at least one sgRNA targeting a gene’s
ORF. Thus, from the 45 significant gene hits described in the paper
(cutoff FDR<0.25), the subset of 41 that were targeted for a dele-
tion of their transcription start site (TSS) were selected and are dis-
played in Figure 1, B and C. The predicted on-target efficiency of
each sgRNA was calculated using the Rule Set II system (Doench
et al. 2016).
Cell culture
HeLa, HCT116, and HEK293T were cultured on Dulbecco’s
modified Eagles medium (DMEM; Sigma-Aldrich D5671) supple-
mented with 10% fetal bovine serum (FBS; Thermo Fisher
Scientific 10500064), 1% L-glutamine (Thermo Fisher Scientific
25030024), 1% penicillin-streptomycin (Thermo Fisher Scientific
15140122). Cells were grown at 37°C and 5% CO2 and passaged












Figure 4. Applying DNA-PKcs inhibition to pooled CRISPR-del screens. (A) Testing the functional benefit of DNA-PKcs inhibition. (Left) Experimental
setup, with pgRNAs targeting the transcription start site (TSS) of the essential gene RPS5. A positive control sgRNA pair (P+) target the gene open reading
frame and thus cause loss of function independent of deletion. (Right) Viability assays with pgRNAs targeting the nonessential AAVS1 locus. (Bottom)
Viability assays after RPS5 TSS deletion (mean, standard deviation, one-tailed paired t-test). (B) Design of a typical pooled high-throughput screen to iden-
tify essential genes. (C) Composition of pgRNA library targeting both essential genes’ TSS and nonessential neutral loci. (D) Log2 fold-change (LFC) in abun-
dance of indicated pgRNAs compared with day 0. Significance calculated by two-tailed t-test. (E) Hits reported by MAGeCK at two timepoints. Negative
log10 false-discovery rate (−log10FDR) for treated and untreated samples are indicated in the y- and x-axis, respectively. Each point represents a target. A hit
is called a true positive (TP) if it is targeting an essential gene and has an FDR <0.25. Points above the diagonal indicate hits with a lower FDR (higher −log10-
FDR) in the treated sample. Numbers in plot reflect TPs in each combination of treated/untreated cells. (F) pgRNAs targeting ERCC1 TSS: read coverage for
untreated and treated samples at 1 wk. (G) Fold-change variation for individual ERCC1 pgRNAs across timepoints: x-axis, timepoint (0, 1, and 3 wk); y-axis,
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pgRNA design and cloning
pgRNAs were designed using CRISPETa (http://crispeta.crg.eu/)
and cloned into the pDECKO backbone as described previously
(Pulido-Quetglas et al. 2017). Off-target filters did not allow fewer
than three mismatches for each sgRNA sequence. No positive or
negative masks were applied in the search. The minimum individ-
ual score was set at 0.2; the minimum paired score, at 0.4. The
pgRNAs were then manually selected from the output list. All
sgRNA sequences may be found in Supplemental Figure S11.
Inhibitors
Allmolecules used in this study are commercially available:M3814
(MedChemExpress HY-101570), KU57788 (MedChemExpress HY-
11006), NU7026 (MedChemExpress HY-15719), LTURM34
(MedChemExpress HY-101667), DMNB (ToChris 2088), and
SCR7 Pyrazine (Sigma-Aldrich SML1546). Ten millimolar stocks
(and 5 mM for NU7026, owing to solubility limitations) were pre-
pared by resuspension in dimethylsulfoxide (DMSO; Sigma-
Aldrich D4540).
Transfection and lentiviral transduction
For transfection experiments, 70% confluent 12-well plates were
transfected using Lipofectamine 2000 (Thermo Fisher Scientific
11668019) with 1250 ng of pDECKO plasmid following the pro-
vider’s guidelines. After 6 h, transfection media was replaced for
fresh complete DMEM (10% FBS, 1% L-glutamine, and 1%penicil-
lin-streptomycin), and the corresponding small molecule was add-
ed to media for 18 h. The treatment was finished by replacing the
media with complete DMEM. After 1 d, cells were selected with
puromycin (2 µg/mL).
For lentiviral infection experiments, cells were spin-infected
at a 0.3 MOI in the presence of DMEM (10% FBS, 1% L-glutamine)
and hexadimethrine bromide (8 µg/mL; Sigma-Aldrich 107689) at
2000 rpm, during 1.5 h at 37°C. After 0, 5, 10, 24, 48, and 72 h, in-
fection media was replaced for fresh complete DMEM (10% FBS,
1% L-glutamine, and 1% penicillin-streptomycin), and the corre-
sponding small molecule was added to media for 18 h. The treat-
ment was finished by replacing the media with complete DMEM
and puromycin (2 µg/mL) to start the selection.
Flow cytometry
After 5 d of puromycin selection, cells were trypsinized, resuspend-
ed in PBS, and incubated for 30min at room temperature (RT) with
the human α-plexin D1 mouse monoclonal antibody (1:150 dilu-
tion; R&D systems MAB4160). Cells were washed twice with PBS
and incubated for 30 min at RT with an α-mouse IgG secondary
goat antibody conjugated to the APC fluorochrome (1:200 dilu-
tion; eBioscience 17-4010-82). Cells were washed and resuspended
in PBS, processed with the LSRII SORP flow cytometer, and ana-
lyzed with FlowJo v10 software. A total of 10,000 cells per sample
are sorted. Cell population is selected in the SSC-A/FSC-A plot.
Single cells are gated in the FSC-H/FSC-A plot. Finally, the APC-
positive population is set in the mCherry/APC plot in the control
sample and expanded to all the other samples without modifica-
tion. The fraction of plexin D1–negative singlet cells is calculated
by gating plexin D1–positive singlet cells, normalizing to a nontar-
geting control and subtracting the value to one (negative cells = 1−
positive cells). An example of the gating strategy may be found in
Supplemental Figure S12. Single-cell imagingwas performed using
ImageStream (Luminex) and analyzed with IDEAS software.
Genomic PCR
After 5 d of puromycin selection, cells were collected and genomic
DNA (qDNA) was extracted using a GeneJET genomic DNA purifi-
cation kit (Thermo Fisher Scientific K0722). Genomic PCRwas per-
formed using GoTaq G2 DNA polymerase (Promega M7841) from
10 ng gDNA. The PCR primers are the following ones: PLXND1
(forward, 5′-AGTCTAGGTTCTGAATCTGTCGC-3′; reverse, 5′-CA
AACACTGTAGCTCTGCTCC-3′) andMALAT1 enhancer (forward,
5′-CCTGCTATGAACTGACCCATG-3′; reverse, 5′-CCTGAACAGT
CAGTCCATGCT-3′).
TOPO cloning and Sanger sequencing of deleted alleles
The PLXND1 KO band and MALAT1 enhancer full-length and KO
bands obtained with the genomic PCRs was gel-purified using the
GeneJET gel extraction andDNA cleanupmicro kit (Thermo Fisher
Scientific K0831) and ligated into a backbone vector using the
TOPO TA cloning kit (Thermo Fisher Scientific 45-0030). Stbl3-
competent cells were transformed with the ligation product, colo-
nies were expanded, and Sanger sequencing was performed
(MicroSynth GmBH) using the same reverse primers as used for
the PCR.
Genomic Quantitative PCR
After 5 d of puromycin selection, cells were collected and genomic
DNA (qDNA) was extracted using a GeneJET genomic DNA purifi-
cation kit (Thermo Fisher Scientific K0722). Quantitative real-time
PCR (qPCR) from 10 ng of gDNA was performed using GoTaq
qPCR master mix (Promega A6001) on a TaqMan Viia 7 real-time
PCR system. Target sequence primers for PLXND1 “wild-type” am-
plification (forward, 5′-GGCAACTGTGTTTGGCACTG-3′; reverse,
5′-GGAACCAGAATGGTTCTTGCC-3′), PLXND1 inversion ampli-
fication (forward, 5′-GGCAACTGTGTTTGGCACTG-3′; reverse,
5′-CAAACACTGTAGCTCTGCTCC-3′), MALAT1 enhancer “wild-
type” amplification (forward, 5′-GCTGGGGAATCCACAGAG
AC-3′; reverse, 5′-CATCTCAGCCCTTGTTATCCTG-3′, and LDHA–
forward, 5′-TGGGCAGTAGAAAGTGCAG-3′; reverse, 5′-TACCAG
CTCCCACTCACAG-3′. Target sequence primers were normalized
to primers targeting the distal, nontargeted gene LDHA. Data were
normalized using the ΔΔCt method (Schmittgen and Livak 2008).
Protein extraction and western blot
After pgRNA transfection and 18 h of vehicle/M3814 treatment,
HeLa cells were collected in urea lysis buffer containing 20 mM
HEPES (pH 8.0), 9.0 M urea, 2.5 mM sodium pyrophosphate,
1 mM β-glycerol-phosphate, and 1 mM sodium orthovanadate.
Lysates were sonicated and clarified by centrifugation. Protein
concentration was measured using the Bio-Rad protein quantifica-
tion reagent (Bio-Rad Laboratories 5000006), and total protein ex-
tracts (50 µg) were resolved by SDS-PAGE on a 6% acrylamide gel.
Proteins were blotted onto PVDF membranes (Novex, Thermo
Fisher Scientific IPFL00010). The membranes were blocked in 5%
BSA in TBS- 0.1% tween and incubatedwithin the indicated prima-
ry antibodies: total DNA-PKcs Y393 (Abcam ab32566), pS2056
DNA-PKcs (Abcam ab124918), α-tubulin (Sigma-Aldrich T6199).
The signal was detected using the corresponding fluorescence sec-
ondary antibodies: IRDye 680RD goat anti-mouse (Li-Cor
Biosciences 925-68070) and IRDye 800CW goat anti-rabbit (Li-
Cor Biosciences 925-32211).
Cell viability assay
CellTiter-Glo 2.0 cell viability assay (Promega G9241) was per-
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thousand cells per well were seeded in 96-well white polystyrene
plates (Corning, Sigma-Aldrich CLS3610-48EA), and cell viability
was measured in technical duplicates during four consecutive
days (0, 24, 48, 72 h) according to the manufacturer’s protocol.
Luminescence was measured using a Tecan reader Infinite 200.
Generation of Cas9 stable cell lines
HeLa cells were infected with lentivirus carrying the Cas9-BFP
(blue fluorescent protein) vector (Addgene 52962). HCT116 and
HEK293T were transfected with the same vector using
Lipofectamine 2000 (Thermo Fisher Scientific 11668019). All cell
types were selected with blasticidin (4 µg/mL) for at least 5 d and
selected for BFP-positive cells twice by FACS.HeLa cells were infect-
ed with lentivirus carrying the DDCas9-mVenus vector (Addgene
90085). HeLa cells with DDCas9-mVenus were selected with zeo-
cin (70 µg/mL) for at least 5 d and selected for mVenus-positive
cells by FACS.
Design of CRISPR-del library
pgRNAs were designed using CRISPETa (http://crispeta.crg.eu/)
with the same parameters as in section “pgRNA Design and
Cloning.” Three to 10 pgRNAs were designed to target essential
protein-coding genes and intergenic regions as neutral controls.
Essential genes were collected by literature search and encode es-
sential ribosomal proteins and oncogenes. Neutral control regions
comprise randomly sampled intergenic regions >10 kb from the
nearest annotated gene. The library was synthesized and packaged
into lentivirus by VectorBuilder (Germany). The library sequence
is available in Supplemental File S1.
Pooled CRISPR-del screen for gene essentiality
HeLa DDCas9-mVenus cells were spin-infected with lentiviruses
carrying the library of mixed pgRNAs at 0.35 and 0.6 MOI with
coverage of 500-fold (pgRNA sequence to cells) in the presence
of DMEM (10% FBS, 1% L-glutamine) and hexadimethrine bro-
mide (8 µg/mL; Sigma-Aldrich 107689) at 2000 rpm for 1.5 h at
37°C. After the spin down, the infection media was replaced for
fresh complete DMEM (10% FBS, 1% L-glutamine, and 1%penicil-
lin-streptomycin). Sixteen hours post infection, media was re-
placed with complete DMEM and puromycin (2 µg/mL) to select
for successfully infected cells. Cells were kept under selection for
6 d. After selection (7 d after infection) cells were split in three
populations: One was collected (time point 0 [T0]) and stored at
−20°C; the second was kept in culture, and stabilization of DD-
Cas9 was effected by adding 400 nM Shield1 for 3 d; and the third
was kept in culture, 400 nM Shield1was added for 3 d, and 300 nM
of M3814 was added to media for 18 h. Cells were kept in culture
and passaged every 2 d. One week after T0 (time point 1 [T1])
and 3wk after T0 (timepoint 3 [T3]), cells were collected and stored
at −20°C. Total gDNA from all collected cells was extracted follow-
ing themanufacturer’s instructionswith the blood and cell culture
DNA midi kit (Qiagen). pgRNAs were amplified from genomic
DNA usingNEBNext Ultra II Q5mastermix (NEB), customprimers
with the sequencing adaptors, and sequencing indexes. In total,
40 µg of each sample was amplified with 25 cycles in 50-µL reac-
tion steps (2 µg of DNA at each step) at an annealing temperature
of 52°C. All PCR products were pooled and purifiedwith SPRIselect
beads (Beckman Coulter) following the manufacturer’s instruc-
tions. The quality and quantity of the sample preparation were
checked with Agilent high sensitivity DNA chips with a
Bioanalyzer (Agilent) and Qubit dsDNA HS assay kit (Invitrogen).
Samples were sequenced at 3000-fold coverage (reads to pgRNA se-
quence) by paired-end (PE) 150-bp reads.
Screen data processing
FASTQ files were processed using CASPR (Bergadà-Pijuan et al.
2020) using adapters ACCG and AAAC for forward and reverse
reads, respectively. The resulting count table was used for down-
stream analysis. LFCs for each pgRNA were computed from the
count table normalized as the fraction of total reads per sample.
To identify gene hits, the count table was used as input for
MAGeCK (Li et al. 2014). For each timepoint, hits were detected us-
ing T0 as control, selecting an FDR gene test threshold of 0.25
(gene-test-fdr-threshold 0.25). MAGeCK output files were pro-
cessed with an in-house Python script (Supplemental Code).
Read counts and processed data are available in Supplemental
Files S2 and S3.
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